| Name | Minocycline hydrochloride |
| Description | Minocycline hydrochloride (Minocycline HCl) is a tetracycline antibiotic with excellent absorption and tissue penetration that is used for several bacterial infections as well as treatment of acne. Minocycline hydrochloride can cause both an acute hepatitis-like syndrome occurring within 1 to 3 months of starting therapy or a more insidious chronic hepatitis with autoimmune features typically after long-term treatment. |
| In vitro | Minocycline exhibits significant neuroprotective effects in models of cerebral ischemia, traumatic brain injury, Huntington's disease, and Parkinson's disease. Its neuroprotective properties may involve the inhibition of 5-lipoxygenase (an inflammatory enzyme associated with brain aging). Additionally, Minocycline's activity is linked to the inhibition of protein synthesis. |
| In vivo | Minocycline inhibits the release of cytochrome c mediated by the permeability transition in mitochondria. This inhibition by minocycline on cytochrome c release has been demonstrated in vivo, in cells, and isolated mitochondria. Additionally, minocycline suppresses the activity of inducible caspase-1 and caspase-3, inducible nitric oxide synthase (iNOS), and p38 mitogen-activated protein kinase (MAPK). Following experimental focal ischemia, minocycline reduces the upregulation of caspase-1 and iNOS, thereby decreasing infarct size. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 5 mg/mL (10.12 mM), Sonication is recommended.
DMSO : 257.5 mg/mL (521.32 mM), Sonication is recommended.
Saline : < 1 mg/mL (insoluble)
|
| Keywords | Ventricular arrhythmia | stroke | Potassium Channel | PI3K/Akt | ovarian cancer | neuroprotective | Myocardial ischemia | Mitochondrial ATP-sensitive potassium | Minocycline hydrochloride | Minocycline | MDM-2/p53 | L-type Ca2+ channel | KcsA | Inhibitor | inhibit | infection | Hypoxia-inducible factors | HIFs | HIFProlylHydroxylase | HIF-PH | HIF/HIFProlylHydroxylase | HIF/HIF Prolyl-Hydroxylase | HIF/HIF ProlylHydroxylase | HIF Prolyl-Hydroxylase | HIF ProlylHydroxylase | HIF | cerebral ischemia | Calcium Channel | Ca2+ channels | Ca channels | Bacterial | Apoptosis | Antibiotic | acinetobacter |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | 2,4,6-Tri-tert-butylphenol | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Formamide | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Glycometabolism Compound Library | Failed Clinical Trials Compound Library | Bioactive Compound Library | Approved Drug Library | Hematonosis Compound Library | Toxic Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Stem Cell Differentiation Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
United States
